- Home
- Publications
- Publication Search
- Publication Details
Title
Ceftolozane/tazobactam: place in therapy
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume 16, Issue 4, Pages 307-320
Publisher
Informa UK Limited
Online
2018-03-01
DOI
10.1080/14787210.2018.1447381
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany
- (2018) Harald Seifert et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes
- (2018) B. Dietl et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013–2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility
- (2018) Dee Shortridge et al. Microbial Drug Resistance
- Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae
- (2017) Richard R. Watkins et al. Expert Review of Anti-Infective Therapy
- Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam
- (2017) Marc Xipell et al. Future Microbiology
- Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant
- (2017) Maddalena Peghin et al. INFECTION
- Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy
- (2017) Daniele Roberto Giacobbe et al. INFECTION
- Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
- (2017) Matteo Bassetti et al. INTENSIVE CARE MEDICINE
- Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa
- (2017) Aurélien Dinh et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model
- (2017) Rachel L. Soon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods
- (2017) Frieder Schaumburg et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers
- (2017) Tommaso Giani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
- (2017) Senthil Natesan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy
- (2017) Ivan Gentile et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)
- (2017) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam
- (2017) Nadia Castaldo et al. Journal of Global Antimicrobial Resistance
- Ceftolozane–tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013–2015)
- (2017) M.A. Pfaller et al. Journal of Global Antimicrobial Resistance
- Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
- (2017) Vimalanand Prabhu et al. JOURNAL OF MEDICAL ECONOMICS
- Real-world Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States
- (2017) Jason M Pogue et al. Open Forum Infectious Diseases
- Real-world Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas
- (2017) Kimberly D Leuthner et al. Open Forum Infectious Diseases
- Physical compatibility of ceftolozane–tazobactam with selected i.v. drugs during simulated Y-site administration
- (2016) Abrar K. Thabit et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations
- (2016) Rachel L. Soon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
- (2016) Belén Gutiérrez-Gutiérrez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study
- (2016) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation
- (2016) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
- (2016) Juan José Castón et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states
- (2016) Antonio L. Velez Perez et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam
- (2016) Alberto Hernández-Tejedor et al. INFECTION
- Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
- (2016) Joseph L. Kuti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial Resistance
- (2016) Hilary D. Marston et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
- (2016) Jennifer A. Huntington et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam
- (2016) Lauren K. Flynt et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient
- (2016) Samuel L. Aitken et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy
- (2016) Derek N. Bremmer et al. PHARMACOTHERAPY
- Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-ResistantPseudomonas aeruginosa
- (2016) Stephen B. Vickery et al. PHARMACOTHERAPY
- Ceftolozane/Tazobactam
- (2015) Allana J. Sucher et al. ANNALS OF PHARMACOTHERAPY
- In VitroActivity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study
- (2015) Eliana S. Armstrong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains
- (2015) Mark D. Gonzalez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Ceftolozane plus Tazobactam Studied in anIn VitroPharmacokinetic Model of Infection
- (2015) Alasdair P. MacGowan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-ResistantPseudomonas aeruginosa: Table 1.
- (2015) Michael S. Gelfand et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study
- (2015) D.R. Giacobbe et al. CLINICAL MICROBIOLOGY AND INFECTION
- Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis
- (2015) Joseph L. Kuti et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
- (2015) Hadas Ofer-Friedman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections
- (2015) Jordan L. Liscio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
- (2015) Alan J. Xiao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination
- (2015) Jonathan C. Cho et al. PHARMACOTHERAPY
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
- (2015) Chul Kim et al. JAMA Internal Medicine
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals
- (2014) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
- (2014) Myra Wooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
- (2014) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model
- (2014) Brian D. VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
- (2014) Gurudatt Chandorkar et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
- (2012) Bartolomé Moyá et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
- (2011) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality
- (2011) M. TUMBARELLO et al. EPIDEMIOLOGY AND INFECTION
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a New Cephalosporin, CXA-101 (FR264205), against -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients
- (2010) L. Zamorano et al. CLINICAL MICROBIOLOGY AND INFECTION
- Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus -lactamase-producing Enterobacteriaceae
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1
- (2010) E. Riera et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
- (2008) Johann DD Pitout et al. LANCET INFECTIOUS DISEASES
- Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
- (2007) Kenji Murano et al. BIOORGANIC & MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now